S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Oculis Stock Price, News & Analysis (NASDAQ:OCS)

$9.99
+0.17 (+1.73%)
(As of 12/1/2023 ET)
Compare
Today's Range
$9.90
$10.35
50-Day Range
$9.10
$11.75
52-Week Range
$6.26
$14.50
Volume
3,547 shs
Average Volume
17,165 shs
Market Capitalization
$363.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00

Oculis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
240.3% Upside
$34.00 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.36mentions of Oculis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.97) to ($1.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

405th out of 951 stocks

Pharmaceutical Preparations Industry

173rd out of 431 stocks


OCS stock logo

About Oculis Stock (NASDAQ:OCS)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

OCS Stock Price History

OCS Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Wedbush Reaffirms Their Buy Rating on Oculis Holding (OCS)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
What 4 Analyst Ratings Have To Say About Oculis Holding
Oculis Holding AG Wt
Oculis Holding AG (OCS)
Expert Ratings for Oculis Holding
See More Headlines
Receive OCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCS
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.00
High Stock Price Target
$64.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+240.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$960,000.00
Book Value
$3.28 per share

Miscellaneous

Free Float
N/A
Market Cap
$363.54 million
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Riad Sherif M.B.A. (Age 55)
    M.D., CEO & Director
  • Ms. Sylvia Cheung (Age 48)
    Chief Financial Officer
  • Mr. Weibo Ding (Age 52)
    Global COO & GM of China
  • Dr. Bastian Dehmel (Age 52)
    Chief Development Officer & Head of Development
  • Dr. Joanne Chang M.D. (Age 62)
    Ph.D., Head of Medical Affairs & Chief Medical Officer
  • Mr. Páll Ragnar Jóhannesson (Age 42)
    Chief Strategy Officer
  • Dr. Fang Li
    Senior Vice President of Regulatory Affairs
  • Ms. Rebecca Weil
    Chief Commercial Officer














OCS Stock Analysis - Frequently Asked Questions

Should I buy or sell Oculis stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCS shares.
View OCS analyst ratings
or view top-rated stocks.

What is Oculis' stock price target for 2024?

8 analysts have issued twelve-month price targets for Oculis' stock. Their OCS share price targets range from $23.00 to $64.00. On average, they predict the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 240.3% from the stock's current price.
View analysts price targets for OCS
or view top-rated stocks among Wall Street analysts.

How have OCS shares performed in 2023?

Oculis' stock was trading at $9.2122 at the beginning of the year. Since then, OCS shares have increased by 8.4% and is now trading at $9.99.
View the best growth stocks for 2023 here
.

When is Oculis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our OCS earnings forecast
.

How were Oculis' earnings last quarter?

Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. The business earned $0.25 million during the quarter, compared to analysts' expectations of $0.30 million.

Who are Oculis' major shareholders?

Oculis' stock is owned by many different institutional and retail investors. Top institutional investors include Pivotal bioVenture Partners Investment Advisor LLC (6.10%), Nan Fung Group Holdings Ltd (1.67%) and Wolverine Asset Management LLC (0.02%).

How do I buy shares of Oculis?

Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OCS) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -